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Abstract
Background: Islet 1 (ISL1), a LIM-homeodomain transcription factor is essential for promoting pancreatic islets proliferation
and maintaining endocrine cells survival in embryonic and postnatal pancreatic islets. However, how ISL1 exerts the role in
adult islets is, to date, not clear.
Methodology/Principal Findings: Our results show that ISL1 expression was up-regulated at the mRNA level both in
cultured pancreatic cells undergoing glucose oxidase stimulation as well in type 1 and type 2 diabetes mouse models. The
knockdown of ISL1 expression increased the apoptosis level of HIT-T15 pancreatic islet cells. Using HIT-T15 and primary
adult islet cells as cell models, we show that ISL1 promoted adult pancreatic islet cell proliferation with increased c-Myc and
CyclinD1 transcription, while knockdown of ISL1 increased the proportion of cells in G1 phase and decreased the proportion
of cells in G2/M and S phases. Further investigation shows that ISL1 activated both c-Myc and CyclinD1 transcription
through direct binding on their promoters.
Conclusions/Significance: ISL1 promoted adult pancreatic islet cell proliferation and probably by activating c-Myc and
CyclinD1 transcription through direct binding on their promoters. Our findings extend the knowledge about the crucial role
of ISL1 in maintaining mature islet cells homeostasis. Our results also provide insights into the new regulation relationships
between ISL1 and other growth factors.
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Introduction
Pancreatic islets in mouse embryos are developed between
embryonic day (E) 13.5 and 15.5 [1,2]. After birth, the number of
islet cells is determined by the balance of cell renewal and cell loss
[3]. The dynamic change of islet cells number is essential in
maintaining euglycemia and thus it is important to understand
how islet cells balance in the adult pancreas is achieved, speci-
fically the mechanisms involved in stimulating pancreatic islet cells
growth and preventing pancreatic islet cells from apoptosis. The
growth rate of pancreatic islet cells is normally low but changes in
response to different stimuli. The cell death or apoptosis is also an
important factor in maintaining the appropriate number of islet
cells. Increasing reactive oxygen species (ROS) concentration is
one of the major causes to induce apoptosis of cells. It is conti-
nuously derived from glucose metabolism and cannot be effectively
eliminated by endogenous antioxidant enzymes. Pancreatic islet
cells undergo apoptosis in either physiological or pathological con-
ditions. There is also an evidence that pre-existing b-cells are the
major source of new b-cells during adult life span and after
pancreatectomy in mice [4]. However, the exact mechanisms
involved in the regulation of these processes are not yet clarified. In
particular, the factors involved in these important physiological or
pathological conditions are not fully identified.
Insulin gene enhancer binding protein-1 (ISL1), which belongs
to LIM homeobox gene family, was first discovered and cloned in
1990 [5]. ISL1 is mainly expressed in adult islet endocrine cells (a,
b, c, e) as well in the central nervous system [6,7]. As a key
transcription factor, the functions of ISL1 involve cell fate
specification and embryonic development. In pancreas its func-
tion is twofold: 1) control the four endocrine islet cell lineages
development and 2) control of dorsal pancreas mesenchyme
development. Complete loss of dorsal pancreatic mesenchyme and
endocrine islet cells was found in ISL1 knock-out mice embryos. It
has also been shown that ISL1 could regulate the expression of
several islet specific genes, such as proglucagon/glucagon (a cells),
somatostatin (c cells), amylin (d cells) and insulin (b cells), although
it is not the master regulator for these genes [8,9,10,11]. However,
it is not clear whether ISL1 plays more important roles rather than
the regulation of these endocrine hormones secretion in postnatal
pancreatic islets. Recent studies demonstrate that ISL1 is required
for proliferation, migration and survival of cardiac progenitor cells
[12]. It also promotes proliferation and repairing of injured motor
neurons [13,14]. Overexpressing ISL1 in endothelial cells and
mesenchymal stem cells can promote blood vessel formation [15].
ISL1 is also involved in the establishment of pancreatic endocrine
cells during the secondary transition (E13.5–E15.5) and controls
the proliferation and survival of endocrine cells during embryonic
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islets are yet not clear.
Based on reports that ISL1 can promote some types of cell
proliferation as mentioned above, we designed this study in order
to investigate whether ISL1 plays roles in maintaining the balance
of islet cell renewal and cell loss. We show that ISL1 can promote
adult pancreatic islet cells proliferation and attenuate cell apoptosis
against oxidative stress. The mechanism involving ISL1 in pro-
moting adult pancreatic islet cells proliferation includes the direct
activation the cell autonomous factors c-Myc and CyclinD1. Our
findings advance our understanding of the roles of ISL1 in adult
pancreas and provide insights into the regulation of adult pan-
creatic cell proliferation.
Results
ISL1 was highly expressed in adult pancreatic islets
The important role of ISL1 in pancreatic islet development has
been well established. However, its role in adult pancreatic islets
remains unclear. The high level of ISL1 expression in adult
pancreatic islets indicates that ISL1 must play important tissue
specific roles. We previously reported that ISL1 enhances the
transcriptional activation of the insulin gene in vitro [17]. In order
to explore the biological functions of ISL1 in adult pancreatic
islets, we detected the expression of ISL1 in different diabetes
animal models. To our surprise, the increasing expression of ISL1,
compared to normal control mice, was detected in all diabetes
models, which is not parallel to the expression of insulin (Fig. 1A).
The results indicate that ISL1 may play other roles in diabetic
mice other than regulating insulin.
ISL1 reduced apoptosis in pancreatic HIT-T15 cells
It has been reported that ISL-1 controls the proliferation and
survival of endocrine cells in postnatal pancreas [16]. Considering
that pancreatic islet cells are challenged by continuous oxidative
stress derived from the glucose metabolism throughout life, we
suspected that ISL1 plays a role in anti-oxidative stress mecha-
nism. We used glucose oxidase (GO) to generate H2O2 from
glucose, mimicking oxidative stress in HIT-T15 (a pancreatic b-
cell line) cells. The flow cytometry (FCM) results showed that GO
strongly promoted the production of ROS (Fig. 1B and Fig. S1)
and increased the level of apoptosis (Fig. 1C and Fig. S2), in a
dose-dependent manner (0–100 mU/mL). Real-time RT-PCR
results showed that GO also dynamically changed the level of ISL1
expression, with a peak at 5 mU/mL of GO (Fig. 1D).
To further confirm the anti-apoptosis role of ISL1, ISL1-specific
siRNA (ISL1-siRNA) was designed and transferred into HIT-T15
cells. The expression of ISL1 at both mRNA and protein levels
was significantly reduced by ISL1-siRNA compared to non-silence
siRNA (data not shown). The FCM result showed that knockdown
of ISL1 could increase HIT-T15 cells apoptosis three folds
regardless GO stimulation (Fig. 1E). These results implied that
ISL1 could protect cells against apoptosis under physiological or
oxidative stress conditions.
ISL1 promoted pancreatic islet cells proliferation
To further define whether ISL1 plays a role in adult islets, islet
mass were isolated from adult Sprague-Dawley (SD) rats and
infected with ISL1 overexpressing lentivirus or ISL1-siRNA lenti-
virus (multiplicity of infection, MOI=10). The infection efficiency
reached approximately 53% and 66%, respectively (Fig. 2A). Real-
time PCR and Western blotting results showed that the expression
level of ISL1 was ameliorated ten folds in ISL1 overexpressed islet
cells (Fig. 2B, 2C) and was attenuated to 30% (Fig. 2D, 2E) in ISL1
knockdown islet cells, which provided a model for further study.
To examine the impact of ISL1 on the proliferation of adult
pancreatic cells, the cell cycle profile was analyzed using pro-
pidium iodide staining and flow cytometry. Compared with the
control (infected with control lentivirus), ISL1 overexpression was
associated with a decreased cell population in G0/G1 phases (from
76.2761.17% to 66.7261.62%) and an increased cell population
in the G2/M and S phases (Fig. 3A). Conversely, adult islet mass
exposed to ISL1-siRNA lentivirus exhibited an increase in the
proportion of cells in G1 phase (from 76.7660.67% to 82.746
0.92%) and a decrease in the proportion of cells in G2/M and S
phases (Fig. 3B). These data indicate that ISL1 plays a role in
promoting adult pancreatic cells proliferation.
Subsequently, we employed the EdU incorporation assay, a
more sensitive and specific method [18,19], to further define the
function of ISL1 in promoting cell proliferation. The number of
EdU positive cells was increased by 2.5 folds in ISL1 overex-
pressing adult islets cells relative to control cells (Fig. 3C, 3E).
More importantly, the number of EdU positive cells in ISL1-
siRNA lentivirus-infected cells was reduced by 40% relative to that
of the cells infected with non-silencer siRNA lentivirus (Fig. 3D,
3E). These results indicate that the knockdown of ISL1 could
inhibit the proliferation of adult islets in vivo, while the overex-
pression of ISL1 promotes adult pancreatic islet cells proliferation.
We also constructed a stable ISL1 overexpressing HIT-T15 cell
line with the pcDNA3.1-ISL1 expression plasmid and a stable
ISL1 knockdown HIT-T15 cell line with ISL1-siRNA. RT-PCR
and Western blotting results showed that both overexpression
(Fig. 4A) and knockdown (Fig. 4B) were established successfully in
cell lines. Then, cell proliferation was determined by CCK-8
analysis. As shown in Fig. 4C, stable transfection of pcDNA3.1-
ISL1 expression plasmid promoted the proliferation of HIT-T15
cells three folds relative to that of with pcDNA3.1 (control) after
72 h culture. As expected, the knockdown of ISL1 inhibited cells
growth by 20% compared to inhibition with non-silencer siRNA
after 48 h culture (Fig. 4D). EdU assay also showed more EdU
positive cells in ISL1 overexpressing cells (Fig. 4G) and less EdU
positive cells in ISL1 knockdown (Fig. 4H) cells, indicating that
ISL1 promoted cell proliferation. These results are well in
agreement with cell-cycle analysis that showed a decrease (from
75.9461.45% to 63.7861.76%) of the percentage of cells in G0/
G1 phase and an increase (from 24.0561.45% to 36.2161.76% )
in the G2/M and S phases in ISL1 stable HIT-T15 cells (Fig. 4E).
In contrast, ISL1 knockdown increased cell population in G0/G1
phase from 76.5460.28% to 86.2760.56% and decreased cell
population in the G2/M and S phases from 23.4560.28% to
13.7360.56% (Fig. 4F). Colony formation assays revealed that
ISL1 overexpressing cells resulted in a significant increase in colony
number compared with the control cells; while ISL1 knockdown
resulted in a significant decrease in colony number (Fig. 4I). These
results further confirm that ISL1 promotes pancreatic islet cells
proliferation.
ISL1 stimulated islet cells proliferation through the
regulation of cell cycle regulators
Several cell cycle regulators, including CyclinD1, c-Myc, and
CDK4 have been shown to control pancreatic islet cell pro-
liferation in vivo [20,21]. To identify the mechanism of ISL1-
stimulated pancreatic islet cell proliferation, we tested whether the
expression of these established cell cycle regulators was controlled
by ISL1. HIT-T15 cells stably expressing ISL1 were subjected to
real-time RT-PCR analysis for the expression of c-Myc, CyclinD1,
CyclinA and p53. The results indicated that the overexpression of
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and p53, but led to a three-fold increase in CyclinD1 expression
and approximately two folds increase in c-Myc expression, relative
to the control (Fig. 5A, 5B). Consistently, the knockdown of ISL1
did not alter the expression level of CyclinA, but was associated
with the decrease in CyclinD1 expression level by 60% and in c-
Myc expression level by 50% as compared with that in the cells
transfected with non-silencer siRNA (Fig. 5C, 5D). Interestingly,
the knockdown of ISL1 significantly enhanced the expression
of p53 (Fig. 5C). To investigate the biological significance of
ISL1-promoted cell proliferation, we then assessed the trans-
activation activity of ISL1 on c-Myc or CyclinD1 promoters. In
these experiments, HIT-T15 cells with ISL1 overexpression were
transfected with a luciferase reporter construct: firefly luciferase
gene inserted with c-Myc or CyclinD1 promoter. The results
showed that the activation of c-Myc or CyclinD1 promoter
exhibited a dose dependent manner within 1 mg of ISL1 with a
constant amount of 0.2 mg c-Myc (Fig. 5E) or 1 mg of ISL1 with a
constant amount of 0.2 mg CyclinD1 (Fig. 5F). These results
indicate that ISL1 is able to activate the c-Myc and CyclinD1
Figure 1. ISL1 was highly expressed in adult pancreatic islets and could reduce apoptosis in HIT-T15 cells. (A) Relative mRNA
expression level of insulin in pancreatic islets from STZ mice (n=6), Akita mice (n=5) and db/db mice (n=6) were measured by real-time RT-PCR.
C57BL/6 mice (n=6) were used as controls to STZ mice and Akita mice, db/w mice (n=6) were as controls to db/db mice. Each bar represents mean
6 SD (**p,0.01, *p,0.05, vs. the controls). (B) Level of ROS production was measured by flow cytometry analysis in HIT-T15 cells treated with
glucose oxidase (GO) at various concentrations (0–100 mU/mL) for 4 h. (C) Level of apoptosis rate was measured by flow cytometry analysis in HIT-
T15 treated with GO at various concentrations (0–100 mU/mL) for 4 h. (D) Relative level of ISL1 mRNA expression in HIT-T15 cells treated with
different GO concentrations was examined by real-time RT-PCR. (E) Level of apoptosis rate was measured by flow cytometry analysis in stable ISL1
knockdown HIT-T15 cells treated with or without 5 mU/mL GO. Each bar represents mean 6 SD from three samples (**p,0.01, vs. the control).
doi:10.1371/journal.pone.0022387.g001
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islet cells proliferation possibly through the activation of the c-Myc
and CyclinD1 promoters and thus increasing the expression of c-
Myc and CyclinD1.
ISL1 activated CyclinD1 or c-Myc transcription by binding
to an evolutionarily conserved site
We have shown that ISL1 could act as a transcriptional
activator of c-Myc or CyclinD1. It is unknown whether ISL1 could
directly control c-Myc or CyclinD1 transcription. Bioinformatic
analysis with MatInspector software revealed a conserved ISL1
binding sequence (TAAT) 645 bp upstream of the ATG trans-
lation start site on the c-Myc promoter (Fig. 6A) and 684 bp
upstream of the ATG translation start site on the CyclinD1
promoter (Fig. 6B). A region covering the ISL1 binding site
located between 2645 and 2650 bp in mouse c-Myc promoter
(Fig. 6A Left) or at 2684 to 2689 bp in mouse CyclinD1
promoter (Fig. 6B Left) was amplified using PCR and was used as
a probe for subsequent electrophoretic mobility shift assays
(EMSA). The results showed that a specific complex was formed
with c-Myc (Fig. 6C, lane 3) or CyclinD1 (Fig. 6D, lane 3) probe.
The complex specificity was confirmed by performing incubation
with a 100-fold molar excess of unlabeled oligonucleotide prior to
the addition of the labeled probes (Fig. 6C, lanes 4–5 and Fig. 6D,
lanes 4–5). The mutation of ISL1 binding site on c-Myc or
CyclinD1 probe failed to compete with the complex formation
(Fig. 6C, lanes 6–7 and Fig. 6D, lanes 6–7). The addition of
normal rabbit IgG, mouse IgG and the unrelated antibody did not
affect the protein-DNA complex formation (Fig. 6C, lane 8 and
Fig. 6D, lanes 8–10), while the complex bands were dramatically
attenuated in the presence of anti-ISL1 antibody, further proving
the specificity of the protein-DNA complex (Fig. 6C, lane 9 and
Fig. 6D, lane 11).
Promoter chromatin immunoprecipitation (ChIP) assay was
performed in HIT-T15 cells to determine if ISL1 could occupy the
c-Myc promoter or CyclinD1 promoter region in vivo. Results
show that the ISL1 antibody specifically immunoprecipitated with
the DNA fragments containing the c-Myc promoter or CyclinD1
promoter in ISL1 overexpressing cells. As shown in Fig. 6E, the
overexpression of ISL1 significantly accentuated the binding of
ISL1 on the c-Myc or CyclinD1 promoter compared to IgG,
suggesting that ISL1 could bind on the c-Myc or CyclinD1
promoter in vivo. As shown in Fig. 6F, ISL1 was recruited to the
Cyclin D1 promoter four folds as compared with lgG, whereas the
binding level on the c-Myc promoter was less than 1.5 folds
relative to IgG. Collectively, these in vitro and endogenous binding
data indicate that ISL1 is a direct regulator of c-Myc and
CyclinD1 transcription in pancreatic b cells.
Discussion
ISL1 is a LIM-homeodomain transcription factor and plays
important roles in the early development of heart, motor neurons
and pancreas at embryonic stage. The expression of ISL1 is down-
regulated in heart cells after birth but remains at a high level in
normal adult islet cells, indicating that ISL1 may have some
functions in terminally differentiated islets. Previous studies pro-
vided evidences that ISL1 is required for proliferation of human
cardiac progenitor cells and motor neurons in injured zebrafish
[13,14]. Furthermore, Du A et al. [16] demonstrated the require-
ment of ISL1 in the maturation, proliferation, and survival of
hormone-producing islet cells after the secondary transition and in
postnatal lives, indicating a crucial role of ISL1 in regulating
endocrine cell growth and survival in young animals [16]. How-
ever, whether ISL1 can prevent islet cells from apoptosis or
promote mature islet cell proliferation are still questions to be
answered.
Our results show that ISL1 knockdown in HIT-T15 cells could
increase the level of apoptosis even in normal cell culture con-
dition. However, the level of apoptosis was dramatically increased
in response to the glucose oxidase stimulation, suggesting that
ISL1 may play roles in anti-apoptosis under the oxidative stress.
Moreover, our study demonstrated that ISL1 could promote
mature pancreatic islet cell proliferation and identified several
Figure 2. The expression of ISL1 was altered in adult islet mass by ISL1 overexpression or knockdown. (A) Infection efficiency (as
indicated by the percentage of GFP positive cells in gated cells) of ISL1 overexpression lentivirus or ISL1-siRNA lentivirus were detected by flow
cytometry analysis after 72 h infection. Real-time RT-PCR (B, D) and Western blotting (C, E) results showed the expression level of ISL1 in ISL1
overexpressed (B and C) islet cells and in ISL1 knockdown (D and E) islet cells. Data represent 3 independent experiments, each performed in
triplicate. Each bar represents mean 6 SD (**p,0.01, vs. the control). Lentivirus without any insert was used as a control.
doi:10.1371/journal.pone.0022387.g002
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could directly bind to MafA in the early stage of pancreas
development [16], but its direct downstream targets in adult
pancreatic islets were uncharacterized. As the adult islet cell
proliferation is a complex process and requires a dynamic change
to meet the requirement of pancreatic function, the regulation of
the islet cell proliferation must result from the orchestration
of many transcriptional factors and growth factors. CyclinD1,
Figure 3. ISL1 promoted proliferation of adult pancreatic cells. Adult pancreatic islet cells infected with ISL1 lentivirus (A) or ISL1-siRNA
lentivirus (B) were subjected to cell cycle analysis by flow cytometry. The data represent 3 independent experiments. The representative cytometric
results from these experiments are shown. EdU incorporation assay was analyzed by confocal microscopy (scale bar, 50 mm; scale bar in magnified
field, 10 mm) in adult islets infected with ISL1 lentivirus (C) or ISL1-siRNA lentivirus (D). (E) The EdU incorporation rate was expressed as the ratio of
EdU positive cells to total Hoechst33342 positive cells. Each bar represents mean 6 SD from 3 samples (**p,0.01, vs. the control).
doi:10.1371/journal.pone.0022387.g003
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was examined by RT-PCR and Western blotting. The cell proliferation was determined by CCK-8 analysis. A total of 1610
3 cells (either stably
overexpressing (C) ISL1 or stably knockdown (D) ISL1) per well were seeded in 96-well plate and measured for their proliferation after 12 h, 24 h, 48 h,
and 72 h. The data represent 3 independent experiments, each performed in triplicate. Each bar represents mean 6 SD (**p,0.01, *p,0.05, vs. the
control). The cell cycle profile was analyzed by flow cytometry in ISL1 (E) and ISL1-siRNA (F) stable HIT-T15 cell lines. EdU incorporation was detected
by confocal microscopy (scale bar, 50 mm) in ISL1 (G) and ISL1-siRNA (H) stable cells. (I) Stable cells were maintained in G418 or puromycin-containing
medium for 21 days before staining with crystal violet and counting for colony numbers. Each bar represents mean 6 SD from 3 samples (**p,0.01,
*p,0.05, vs. the control).
doi:10.1371/journal.pone.0022387.g004
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reported to control the islet cell proliferation during pancreas
development [20,21]. We investigated whether the expression of
these established cell cycle regulators are controlled by ISL1. As a
transcription factor, ISL1 exerts its function by binding to a
consensus sequence TAAT on the promoter of target genes. Our
promoter chromatin immunoprecipitation (ChIP) assay results
revealed that ISL1 could regulate the transcription of c-Myc and
CyclinD1 by directly binding on the c-Myc or CyclinD1 promoter
in vivo. Furthermore, the luciferase assays demonstrated that the
overexpression of ISL1 was positively correlated with the promoter
activity of c-Myc or CyclinD1 promoter, while knockdown of ISL1
inhibited their activity.
Wild-type p53 acts as a potent regulator of the cell cycle,
especially coordinating transcriptional responses to pathological
stress [22]. In response to DNA damage, p53 accumulates in cell
nuclei causing cell arrest at the G1 phase and inducing apoptosis
[23,24]. We found that the overexpression of ISL1 did not affect
the expression level of p53, but the knockdown of ISL1
significantly enhanced the expression of p53 and increased the
apoptosis. Whether p53 is involved in the anti-apoptosis role of
ISL1 in the islet cells requires further investigation. It should be
mentioned that we have observed that ISL1 overexpression also
slightly increased the level of apoptosis of HIT-T15 cells (data not
shown). This phenomenon is possibly due to the high level of
endogenous ISL1 expression in HIT-T15 cells and the overex-
pression of ISL1 may disrupt the orchestration of ISL1 regulation.
We have noticed that EdU incorporation rate in ISL1 expressing
adult islet cells is about 2.5 folds than that in the control (Fig. 3C,
3E). However, the differences are not so obvious in FCM analysis.
Figure 5. ISL1 promoted the expressions of c-Myc and CyclinD1. The mRNA level (A, C) and protein level (B, D) of c-Myc and CyclinD1, Cyclin
A, p53 were analyzed by real-time RT-PCR and Western blotting in ISL1 stable overexpression HIT-T15 cells (A and B) and ISL1 knockdown HIT-T15
cells (C and D). The transcriptional activity of ISL1 was analyzed by luciferase reporter assay. ISL1 activated the promoter of c-Myc (E) or CyclinD1 (F) in
a dose-dependent manner. The data represent 3 independent experiments, each performed in triplicate. Each bar represents mean 6 SD (**p,0.01,
*p,0.05, vs. the control).
doi:10.1371/journal.pone.0022387.g005
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reflecting cell proliferation. EdU incorporation detected the newly
synthesized random DNA regardless of cell cycle phase transition.
The data are expressed as folds of positive islet cells relative to
negative cells. While FCM detected the cell proliferation, repre-
sented by S/G2M phases transition in one cell cycle. Additionally,
as ISL1 target genes, we also noted CyclinD1 was regulated more
significantly than c-Myc by ISL1. This implies that CyclinD1
might be a more potent downstream factor to mediate the ISL1
proliferation effects in pancreatic islet cells.
In conclusion, ISL1 can promote mature pancreatic islet cells
proliferation and attenuate cell apoptosis against oxidative stress.
c-Myc and CyclinD1 are identified as novel downstream targets of
ISL1 and are involved in ISL1 regulation on the proliferation of
Figure 6. ISL1 band on the c-Myc or Cyclin D1 promoter directly. Consensus binding site (TAAT, box) for ISL1 on the c-Myc (A) or CyclinD1 (B)
promoter was analyzed by Matinspector software. (C and D) Nuclear extracts were subjected to EMSA for the ISL1 proteins binding ability to the
32P-
labeled oligonucleotides containing the consensus sequence of the c-Myc or CyclinD1 promoter. (C) Lane 1, free probe. Lane 2, nuclear extracts from
HIT-T15 cell without transfection. Lanes 3–9, nuclear extracts from HIT-T15 cells transfected with ISL1 expression construct. Lane 3 shows the direct
binding of ISL1. Lanes 4 and 5 show wild-type unlabeled oligonucleotide competition. Lanes 6 and 7 show mutant unlabeled probe competition.
Lane 8, the mouse normal IgG was used as a negative control. Lane 9, 1 mg anti-ISL1 antibody (H00003670-M05, Abnova) was added. (D) Lanes 1–7,
same as C, Lane 8, rabbit normal IgG was used as a negative control. Lane 9, 1 mg unrelated rabbit anti-GATA4 was added. Lane 10, mouse normal IgG
was used as a negative control. Lane 11, 1 mg mouse anti-ISL1 polyclonal antibody was added. (E and F): ISL1 recruited on the c-Myc or Cyclin D1
promoter was analyzed by ChIP assay. Soluble chromatin was prepared from HIT-T15 cells stably transfected with 2 mg of pcDNA3.1-ISL1 plasmid
followed by immunoprecipitation with antibodies against ISL1. The DNA extractions were amplified using the primers that cover the ISL1 binding
sites on the c-Myc or Cyclin D1 promoter by PCR (E) or real-time PCR (F) with normal IgG as a control. The data represent 3 independent experiments,
each performed in triplicate. Each bar represents mean 6 SD (**p,0.01, *p,0.05, vs. the control).
doi:10.1371/journal.pone.0022387.g006
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crucial role of ISL1 in maintaining mature islet cells homeostasis.
Our results also provide insights into the new regulation relation-
ship between ISL1 and other growth factors.
Materials and Methods
Ethics Statement
The animal experiments were performed in accordance with
the ethical principles and guidelines for scientific experiments on
animals of the Swiss Academy of Medical Sciences (1995). All
protocols were approved by the Animal Care and Use Committee
of Peking University (LA 2010-066). The animals in the post-
prandial state were anesthetized with 5 mg/100 g body weight of
sodium pentobarbital and pancreatic tissue was removed.
Plasmid constructs and recombinant lentivirus
The plasmid construct pcDNA3.1-ISL1 was previously described
[25] and was used as stable transfection. The pLL3.7-ISL1-siRNA
plasmid was commercially constructed by the GeneChem Compa-
ny (Shanghai, China) and was used for stable transfection. The
luciferase reporter constructs c-Myc-luc and CyclinD1-luc were
generous gifts from Prof. Yongfeng Shang (Department of Bio-
chemistryandMolecular Biology, Peking University Health Science
Center).
The sequences of ISL1-siRNA are: sense, GAGACAUGGUG-
GUUUAtt; antisense: UUUCUCCUUGCACCUCtt. The se-
quences of non-silencer siRNA are: sense: UUCUCCGAACGU-
GUCACGUtt; antisense: ACGUGACACGUUCGGAGAAtt. Re-
combinant lentiviruses with ISL1 cDNA or ISL1-siRNA were
obtained from the Genechem Company (Shanghai, China).
Lentivirus infection was carried out following the manufacturer’s
instruction with multiplicity of infection as 10 and rat adult islet cells
were used as target cells. The infection efficiency was detected by
flow cytometry analysis.
Cell cultures, stable cell lines and adult islets isolation
Monolayer cultures of hamster pancreatic islet b cell line HIT-
T15 (ATCC number: CRL-1777) were maintained in RPMI 1640
(GIBCO BRL) complete medium, which contained 2 mM/L
glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, and
10% fetal bovine serum. The medium was changed every 1–2
days.
To establish stable cell lines, 2610
5 HIT-T15 cells were
plated into a 60 mm culture dish. When approximately 50%
confluence was reached, HIT-T15 cells were transfected with 2 mg
pcDNA3.1-ISL1 plasmid, or a control pcDNA3.1 plasmid, respec-
tively, with Lipofectamine2000. G418 selection (1000 mg/ml) was
performed and single colonies were picked up at about 21 days.
The cells transfected with pLL3.7-ISL1-siRNA or pLL3.7-non-
silencer were selected using puromycin resistant screening (1 mg/
ml). Identification of stable cell lines were performed using RT-
PCR and Western blotting for quantifying the expression levels of
ISL1.
Pancreatic islets were isolated from 100–120 g male Sprague-
Dawley rats as previously described [26]. Briefly, donor pancreases
were perfused in situ with collagenase V (3 mg/ml, Sigma-Aldrich,
St. Louis, MO, USA), and the pancreatic tissues were harvested
after the perfusion and were further incubated at 37uC with gentle
vortex (375 rpm) for 30 min. Islets were released from the
pancreas and were handpicked. The isolated islets were washed
with Hank’s solution twice at 4uC, counted and cultured in RPMI
complete medium.
Cell proliferation assays and clone formation assay
The pancreatic cell proliferation was measured by performing
WST-8 assay and 5-ethynyl-20-deoxyuridine (EdU) incorporation
assay, using a CCK-8 cell proliferation kit (Dojindo Laboratories,
Kumamoto, Japan) and EdU assay kit (Ribobio, Guangzhou
China), respectively, according to the manufacturers’ instructions.
For CCK-8 assay, cells were seeded into a 96-well plate at
1610
3cells per well with 100 ml complete medium and cultured at
37uC, 10 ml CCK-8 solution was added to each well after 12 h,
24 h, 48 h, and 72 h, respectively. Plates were incubated at 37uC
for 2 h, and then the absorbance at 450 nm was measured with
Microplate Reader (Bio-Rad, La Jolla, CA, USA). All experiments
were done in triplicate and three independent repeating
experiments were performed.
For EdU incorporation assay, cells were cultured in triplicate in
96-well plates at a density of 1610
3 HIT-T15 cells or 50 rat islets
mass per well for 48 h at 37uC, and then 50 mM of EdU was
added to each well and cells were cultured for additional 4 h at
37uC. The cells were fixed with 4% formaldehyde for 15 min at
room temperature and treated with 0.5% Triton X-100 for
20 min at room temperature for permeabilization. After washing
with PBS three times, 100 mlo f1 6ApolloH reaction cocktail was
added to each well and the cells were incubated for 30 min at
room temperature. Then the cells were stained with 100 mlo f
Hoechst33342 for 30 min and visualized under a fluorescent
microscope (Olympus Corporation, Tokyo, Japan). The EdU
positive cells (red cells) were counted using Image-Pro Plus (IPP)
6.0 software (Media Cybernetics, Bethesda, MD, USA). The EdU
incorporation rate was expressed as the ratio of EdU positive cells
to total Hoechst33342 positive cells (blue cells). All experiments
were done in triplicate and three independent repeating experi-
ments were performed.
A total of 1610
5 ISL1 or ISL1-siRNA stable transfection cells
were plated onto a 60-mm culture dish. Cells were maintained in
culture medium supplemented with 1 mg/ml G418 or 1 mg/ml
puromycin for 21 days and stained with crystal violet for colony
counting. The colony diameter greater than 4.5 mm was counted
using IPP 6.0 software. All experiments were done in triplicate and
three independent repeating experiments were performed.
Flow cytometry analysis for cell cycle, apoptosis and ROS
generation
Cell cycle analysis was performed by flow cytometry. Briefly,
cultured cells were trypsinized into single cell suspensions and
fixed with 70% ethanol for 30 min on ice. RNA was degraded by
incubation with 20 mg/ml RNase (Sigma-Aldrich, St. Louis, MO,
USA) for 1 h at 37uC. DNA was labeled with 20 mg/ml pro-
pidium iodide (PI, Sigma-Aldrich) and DNA content was assessed
by FACS Calibur flow cytometry (Becton Dickinson, Franklin
Lakes, NJ, USA) equipped with the ModiFit LT v2.0 software. For
apoptosis analysis, cultured cells were harvested by trypsinization
and washed with PBS. 1610
6 cells from each sample were
processed for Annexin V FITC/PI apoptosis detection (Becton
Dickinson) according to the manufacturer’s instructions.
Reactive oxygen species (ROS) were detected using reactive
oxygen species assay kit C1300 (Applygen, Beijing, China).
Cells were incubated with variable concentrations of glucose
oxidase (0 to 100 mU/mL) in fresh serum-free RPMI1640 for 4 h,
before the absorbance at 530 nm was assessed by FACS Calibur
flow cytometry. Data are presented as the percentage of ROS
positive cells amongst total cells. All experiments were done in
triplicate and three independent repeating experiments were
performed.
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Cells were seeded into a 6-well plate at 1610
5 cells per well and
harvested after 48 h culture. Total RNA extraction was performed
using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) based on
the manufacturer’s instructions. Amplifications were performed in
the ABI 7300 Real-Time RT-PCR System (Carlsbad, CA, USA)
with different primers (Table 1). All annealing temperatures were
60uC. Transcription levels were normalized to 18S rRNA levels.
Each value presents the average of at least 3 independent
experiments.
Western blotting
Western blotting was performed as previously described [27].
Cells were seeded into a 6-well plate at 1610
5cells per well and
were harvested after 48 h culture. Total protein was prepared and
subjected to 12% SDS polyacrylamide gel electrophoresis and
subsequently transferred onto nitrocellulose membranes. Antibod-
ies, including ISL1 (H00003670-M05, Abnova, Taipei, China),
CyclinD1 (ab61758, Abcam, Hong Kong, China), c-Myc (sc-764,
Santa Cruz, CA, U.S.A.) and horseradish peroxidase-conjugated
secondary antibody from Santa Cruz were used.
Luciferase assays
HIT-T15 cells were seeded at a density of 10610
4 per well in a
24-well plate, constructs of c-Myc-luc, CyclinD1-luc, or ISL1 were
transfected using Lipofectamine
TM2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions when cells
reached 60% confluence. The total amount of DNA was kept
constant using pcDNA3.1/b-gal plasmid. Luciferase activity was
measured and normalized to Renilla luciferase activity. All
experiments were done in triplicates and three independent
repeating experiments were performed.
Electrophoretic mobility-shift assay (EMSA)
Nuclear extracts were prepared from HIT-T15 cells. Oligonu-
cleotides used in EMSA assay were labeled with [c-
32P] ATP as
described previously [27]. The sequences of the sense strand of
these oligonucleotides are as follows (ISL1 binding motif is under-
lined and mutant bases are in lower cases):
Wild-type c-Myc probe: 59-ATTAGAGTCGGCTTTTAAT-
TAGTTAACACACAC-39.
Mutant c-Myc probe: 59-ATTAGAGTCGGCTTTgccgTAG-
TTAACACACAC-39.
Wild-type CyclinD1 probe: 59-AATTTAATTTCTTTTT-
TAATTAAAAAAAATGAGT C-39. Mutant CyclinD1 probe:
59-AATTTAATTTCTTTTTgccgTAAAAAAAATGA GTC- 39.
The binding reactions were performed at 4uC (20 ml final volume)
with 10 mg of nuclear protein and 0.25 ng (20 kcpm) of radio-
labeled, double-stranded oligonucleotide in a binding buffer.
Antibody analyses were performed by pre-incubation of nuclear
extract protein with specific ISL1 antibody (Abnova) for 20 min at
4uC prior to addition of the radiolabeled probe. Protein-DNA
complexes were resolved on a 6% native polyacrylamide gel and
visualized by autoradiography.
ChIP assay
HIT-T15 cells were stably transfected with 2 mg of pcDNA3.1-
ISL1 plasmid and cells were harvested after 48 h culture. ChIP
experiments were performed according to the method described
previously [17]. After crosslink reversal, precipitated DNA was
analyzed by PCR for fragments of the c-Myc and CyclinD1
promoters with different primers. The annealing temperatures
were 60uC. The input DNA and immunoprecipitated DNA were
calculated by real-time PCR using SYBRH Green Real-time
PCR Master Mix (TOYOBO, Japan). The data obtained were
normalized to the corresponding DNA precipitated by IgG. c-
Myc: forward (F), 59-AATGCACAGCGTAGTATTCAGGA-39;
reverse (R), 59 GGA GTG AAT TGC CAA CCC AGA 39
(270 bp fragment). CyclinD1: forward (F), 59- AGCTTCGG-
TGTCTGGTTC- 39; reverse (R), 59- ATTCCAGCAACGCT-
CAA GATG- 39 (283 bp fragment).
Type 1 and type 2 diabetes animal models
STZ-induced diabetic mice (male C57BL/6 mice at the age of 8
to 10 weeks, obtained from Department of Laboratory Animal
Science, Peking University, China), were established as described
previously [17]. The mice with stable hyperglycemia (blood glucose
level .20 mmol/L) were used as the type 1 diabetes animal model.
Akita, db/db and db/w mice were provided by Prof. Youfei Guan
(Peking University, China). The Akita mice at 12 weeks of age were
used as an autosomal dominant mutation Mody animal model and
showed hyperglycemia with notable pancreatic b-cell dysfunction.
Db/db mice at 14–16 weeks of age were used as the type 2 diabetes
animal model, which were homozygous for the db gene and, thus,
exhibited an obese, diabetic phenotype. Db/w mice that were
heterozygous for the db gene exhibited a nondiabetic, normal
phenotype were used as controls to db/db mice. The type 1 and
type2 diabetesmiceinthe postprandialstate wereanesthetizedwith
5 mg/100 g body weight of sodium pentobarbital and pancreatic
tissue was removed. RNA was prepared from these tissues and used
for real-time RT-PCR assay.
Statistical analysis
The data are expressed as mean 6 standard deviation (S.D.).
Comparisons between groups were analyzed using Student’s t-test
or ANOVA, and the Student-Newman-Kleuss method was used to
estimate the level of significance. Differences were considered to be
statistically significant at p,0.05.
Supporting Information
Figure S1 Glucose oxidase stimulated ROS production.
Level of ROS production was measured by flow cytometry
Table 1. Primers used in RT-PCR and real-time RT-PCR.
Primers Primer sequences (59–39) Product size (bp)
18SRNA F: GTAACCCGTTGAACCCCATT 151
R: CCATCCAATCGGTAGTAGCG
ISL1 F: CTGCTTTTCAGCAACTGGTCA 123
R: TAGGACTGGCTACCATGCTGT
c-Myc F: GCCACGTCTCCACACATCAG 141
R: TCTTGGCAGCAGGATAGTCCTT
CyclinD1 F: GCGTACCCTGACACCCCTCTC 183
R: CTCCTCTTCGCCTGATCC
CyclinA F: GCCTTCACCATTCATGTGGAT 118
R: TTGCTGCGGGTAAAGAGACAG
p53 F: TTCCACCTGGGCTTCCTG 144
R: GGATAGGTCGGCGGTTCAT
Insulin F: AGGACCCACAAGTGGAACAACT 140
R: CAACGCCAAGGTCTGAAGGT
doi:10.1371/journal.pone.0022387.t001
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various concentrations (0–100 mU/mL) for 4 h. ROS production
exhibited a dose dependent manner with GO concentration.
(TIF)
Figure S2 Glucose oxidase increased the number of
apoptotic cells. Level of apoptosis rate was measured by flow
cytometry analysis. HIT-T15 were treated with GO at various
concentrations (0–100 mU/mL) for 4 h. the numbers of apoptotic
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